The job cuts are part of the drugmaker’s plan to boost profitability after its $63 million acquisition of Monsanto.
Job cuts in Germany are potentially costly because of tight labor protections, according to the report.
A Bayer spokesperson declined Bloomberg‘s request for comment on the layoffs.
The 12,000 job cuts will be completed by the end of 2021.
More articles on pharmacy:
PBM hearing should prompt bill to ban ‘secrecy’ in drug industry, senator says
Republicans tell drugmakers that complying with House probe could hurt their stock prices
Hawaii primary care network opens in-house pharmacy
